Highlights Knight Therapeutics Inc.

Equities

GUD

CA4990531069

Market Closed - Toronto S.E. Other stock markets 15:59:59 2024-07-04 EDT			5-day change	1st Jan Change
5.69 ^CAD	-1.04%		+1.61%	+9.63%

05-09	Knight Therapeutics Up Near 3% After Announcing Supply and Distribution Agreement For ADHD Medication; Despite Mixed Q1	MT
05-09	Transcript : Knight Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Knight Therapeutics Up Near 3% After Announcing Supply and Distribution Agreement For ADHD Medication; Despite Mixed Q1	05-09	MT
Knight Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Knight Therapeutics Brief: Q1 Net loss was $4.546 Million; Revenues were $86.604 Million	05-09	MT
Knight Therapeutics Brief: Entering into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM In Canada and Latin America	05-09	MT
Knight Therapeutics Inc. Reconfirms Earnings Guidance for the Year 2024	05-09	CI
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for Jornay Pm® for Canada and Latin America	05-09	CI
Knight Therapeutics Reports Fourth Quarter Results	03-21	MT
Knight Therapeutics Inc. Provides Revenue Guidance for the Fiscal Year 2024	03-21	CI
Knight Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
Knight Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-21	CI
North American Morning Briefing : Investors -2-	03-21	DJ
Knight Therapeutics Announces Launch of Minjuvi in Brazil	02-29	MT
Knight Therapeutics Brief: Announcing Launch of Minjuvi in Brazil	02-29	MT
Knight Therapeutics Brief: Announcing Regulatory Submission Of Fostamatinib In Brazil	02-21	MT
Knight Therapeutics Inc. Announces Regulatory Submission of Fostamatinib in Brazil	02-21	CI
Knight Therapeutics Announces Launch of Bijuva in Canada	02-06	MT
Knight Therapeutics Brief: Announcing Launch of Bijuva in Canada	02-06	MT
Knight Therapeutics Inc. Announces Launch of Bijuva® in Canada	02-06	CI
Knight Therapeutics Enters Into License Agreement With Amneal Pharmaceuticals For Parkinson's Disease Treatment	01-25	MT
Knight Therapeutics Brief: Entering Into Exclusive License Agreement With Amneal Pharmaceuticals For IPX203	01-25	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Knight Therapeutics Inc.

Equities

GUD

CA4990531069

Highlights

Filters